Bamlanivimab and Etesevimab Improve Symptoms and Associated Outcomes in Ambulatory Patients at Increased Risk for Severe Coronavirus Disease 2019: Results From the Placebo-Controlled Double-Blind Phase 3 BLAZE-1 Trial
Open Forum Infectious Diseases (2022) - Comments
doi: 10.1093/ofid/ofac172  issn: 2328-8957  pubmed: 35493124 

Peter Chen, Gerhard Behre, Corey Hebert, Princy Kumar, Lisa Farmer Macpherson, Peita Louise Graham-Clarke, Inmaculada De La Torre, Russell M Nichols, Matthew M Hufford, Dipak R Patel, April N Naegeli